1. Different cosmetic incision selection in parotidectomy
Qiang ZHANG ; Kairui CHEN ; Yanlin TAN ; Youchun WEI ; Zhongyi CAO ; Jiaxuan QIU
Chinese Journal of Plastic Surgery 2018;34(6):449-452
Objective:
Based on the nature, location and size of parotid tumor, different incisions were chosen and method of selecting the best cosmetic incision for parotid gland tumor operation would be discussed.
Methods:
33 cases of parotid benign tumor patients that received by Department of Oral and Maxillofacial surgery of First Affiliated Hospital of Nanchang University during 2015-2017 were included in this study. According to the size of the tumor location, different incisions, mainly pretragal vertical, pretragal crutch and rhytidectomy incision were selected. The facial nerve and the great auricular nerve were protected during the operation. In 1-month and 3-month follow-up, clinical examination of temporary facial paralysis, salivary fistula, especially the cosmetic outcome after the surgery were evaluated.
Results:
The satisfaction rate of parotid cosmetic incision was significantly higher than that of the traditional group, the incidence of transient facial paralysis, salivary fistula was not statistically significant compared with the traditional incision.
Conclusions
According to the location of parotid tumor, we should choose the proper cosmetic incision approach, which is better than the traditional surgical incision.
2.Comparison of ocular modulation transfer function determined by a ray-tracing aberrometer and a double-pass system in early cataract patients.
Liya QIAO ; Xiuhua WAN ; Xiaogu CAI ; Balamurali VASUDEVAN ; Ying XIONG ; Jiaxuan TAN ; Zheng GUAN ; David A ATCHISON ; Ningli WANG ;
Chinese Medical Journal 2014;127(19):3454-3458
BACKGROUNDThe evaluation of retinal image quality in cataract eyes has gained importance and the clinical modulation transfer functions (MTF) can obtained by aberrometer and double pass (DP) system. This study aimed to compare MTF derived from a ray tracing aberrometer and a DP system in early cataractous and normal eyes.
METHODSThere were 128 subjects with 61 control eyes and 67 eyes with early cataract defined according to the Lens Opacities Classification System III. A laser ray-tracing wavefront aberrometer (iTrace) and a double pass (DP) system (OQAS) assessed ocular MTF for 6.0 mm pupil diameters following dilation. Areas under the MTF (AUMTF) and their correlations were analyzed. Stepwise multiple regression analysis assessed factors affecting the differences between iTrace- and OQAS-derived AUMTF for the early cataract group.
RESULTSFor both early cataract and control groups, iTrace-derived MTFs were higher than OQAS-derived MTFs across a range of spatial frequencies (P < 0.01). No significant difference between the two groups occurred for iTrace-derived AUMTF, but the early cataract group had significantly smaller OQAS-derived AUMTF than did the control group (P < 0.01). AUMTF determined from both the techniques demonstrated significant correlations with nuclear opacities, higher-order aberrations (HOAs), visual acuity, and contrast sensitivity functions, while the OQAS-derived AUMTF also demonstrated significant correlations with age and cortical opacity grade. The factors significantly affecting the difference between iTrace and OQAS AUMTF were root-mean-squared HOAs (standardized beta coefficient = -0.63, P < 0.01) and age (standardized beta coefficient = 0.26, P < 0.01).
CONCLUSIONSMTFs determined from a iTrace and a DP system (OQAS) differ significantly in early cataractous and normal subjects. Correlations with visual performance were higher for the DP system. OQAS-derived MTF may be useful as an indicator of visual performance in early cataract eyes.
Aberrometry ; methods ; Adult ; Aged ; Cataract ; physiopathology ; Female ; Humans ; Male ; Middle Aged ; Visual Acuity ; physiology
3.Recent progress of aptamer‒drug conjugates in cancer therapy.
Jiaxuan HE ; Qiao DUAN ; Chunyan RAN ; Ting FU ; Yuan LIU ; Weihong TAN
Acta Pharmaceutica Sinica B 2023;13(4):1358-1370
Aptamers are single-stranded DNA or RNA sequences that can specifically bind with the target protein or molecule via specific secondary structures. Compared to antibody-drug conjugates (ADC), aptamer‒drug conjugate (ApDC) is also an efficient, targeted drug for cancer therapy with a smaller size, higher chemical stability, lower immunogenicity, faster tissue penetration, and facile engineering. Despite all these advantages, several key factors have delayed the clinical translation of ApDC, such as in vivo off-target effects and potential safety issues. In this review, we highlight the most recent progress in the development of ApDC and discuss solutions to the problems noted above.